Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or the "Company") once again had five high-quality drugs successfully selected in the fifth round of national centralized drug procurement, specifically: Zefei® (Gemcitabine Hydrochloride for Injection), Xinmei® (Decitabine for Injection), Hengjie® (Linezolid Glucose Injection), Fulailin® (Saxagliptin Tablets) and Zechang® (Dabigatran Etexilate Capsules).
Since the implementation of the national centralized drug procurement policy, Hansoh Pharma has responded to the call of the national policy to participate in centralized procurement, and has taken initiatives such as technological innovation, lean production, quality improvement and efficiency enhancement to ensure product quality and market supply, improve drug accessibility, contribute to the society and help build "Healthy China".
Zefei® (Gemcitabine Hydrochloride for Injection)
Zefei® (Gemcitabine Hydrochloride for Injection) was approved for marketing in 2001 as the first generic in China. Zefei® is a key anti-tumor product of Hansoh Pharma, used for the treatment of intermediate and advanced NSCLC, and has won the second prize of the National Science and Technology Progress Award and the China Patent Gold Award successively. In 2012, it took the lead in passing the US FDA certification and was sold to the US market.
Xinmei® (Decitabine for Injection)
Xinmei® (Decitabine for Injection) was first marketed in China in 2013 and was included in the National Reimbursable Drug List in 2017. It is used for treated, untreated, primary and secondary myelodysplastic syndromes (MDS).
Hengjie® (Linezolid Glucose Injection)
Hengjie® (Linezolid Glucose Injection) was approved for marketing as the first generic in China in 2015, and has been included in the National Reimbursable Drug List since its launch. Used for the treatment of infections caused by specific microbial susceptible strains, it has unique pharmacokinetic advantages that bring benefits to patients.
Fulailin® (Saxagliptin Tablets)
Fulailin® (Saxagliptin Tablets) was approved for marketing in 2020. It is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for use with diet control and exercise to improve glycemic control in patients with type II diabetes. The advantages of the DPP-4 inhibitor over conventional hypoglycemic agents include no increased risk of hypoglycemia and a neutral effect on body weight.
Zechang® (Dabigatran Etexilate Capsules)
Zechang® (Dabigatran Etexilate Capsules) was approved for marketing in 2021 and was deemed to have passed the consistency evaluation. Zechang® is a new-generation oral anticoagulant direct factor IIa inhibitor for the prevention of stroke and systemic embolism (SEE) in adult patients with nonvalvular atrial fibrillation (NVAF). It provides patients with a new option of good medication.
The five selected drugs of Hansoh Pharma will greatly significantly reduce the burden of medication for patients in the fields of anti-tumor, anti-infection, diabetes and cardiovascular, improve the standardization of clinical treatment, benefit patients in a wider range, and bring good social benefits. Upholding the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will continue to focus on patient benefits, pursue innovation-driven development, live up to CSR commitments, and help grow China's pharmaceutical industry and protect people's health.